The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial.

Abstract

We evaluated an anti-inflammatory enzyme drug Danzen (Serrapeptase: Takeda Chemical Industries, Ltd.) on 70 patients complaining of breast engorgement. These patients were randomly divided into 2 groups, a treatment group and a placebo group. A single observer, unaware of the group the patients were in, assessed the severity of each of the symptoms and signs of breast engorgement before treatment was commenced, and daily for 3 days, during which therapy was administered. Danzen was noted to be superior to placebo for improvement of breast pain, breast swelling and induration and while 85.7% of the patients receiving Danzen had "Moderate to Marked" improvement, only 60.0% of the patients receiving placebo had a similar degree of improvement. "Marked" improvement was found in 22.9% of the treatment group and 2.9% of the placebo group. These differences were statistically significant (P less than 0.05). No adverse reactions were reported with the use of Danzen. Danzen is a safe and effective method for the treatment of breast engorgement.

• Authors: W H Kee, S L Tan, V Lee, Y M Salmon
• Journal: Singapore medical journal (Singapore Med J) Vol. 30 Issue 1 Pg. 48-54 (Feb 1989) ISSN: 0037-5675 [Print] India
• PMID: 2688125 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Peptide Hydrolases
• serratiopeptidase

Topics

• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Breast Feeding
• Double-Blind Method
• Female
• Humans
• Lactation (drug effects)
• Peptide Hydrolases (therapeutic use)
• Pregnancy
• Puerperal Disorders (drug therapy)